Treatment of Systemic Mast-Cell Disease with Cladribine
Authors:
- Ayalew TefferiATAyalew Tefferi
- Chin-Yang LiCLChin-Yang Li
- Joseph H. ButterfieldJBJoseph H. Butterfield
- H. Clark HoaglandHHH. Clark Hoagland
- 25 January 2001
- journal article
- letter
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 344 (4) , 307-309
Abstract
Cladribine (2-chlorodeoxyadenosine) is a purine nucleoside analogue with activity against various hematologic cancers.1 Because mast cells are derived from hematopoietic stem cells,2 we evaluated the therapeutic activity of cladribine in a patient with interferon alfa–resistant systemic mast-cell disease.Keywords
This publication has 2 references indexed in Scilit: